Powered by Business Wire
Search Results for Topix.net

Cynvenio Biosystems Launches LiquidBiopsy™ Early Access Program for Dynamically Sequencing Patient Tumors from Whole Blood

New program makes LiquidBiopsy platform available for the first time to cancer research centers; enables genomic analysis of solid tumors from blood to advance understanding of disease evolution and targeted treatment

LOS ANGELES--(BUSINESS WIRE)--Cynvenio Biosystems, Inc. today announced the launch of a new commercial program granting early access to its LiquidBiopsy Rare Cell Isolation Platform. The LiquidBiopsy system automates the identification and enrichment of rare tumor cells from standard patient blood draws.

“Our technology has been available as a CLIA lab service for doctors and pharma since 2013”

This program makes it possible for cancer research labs to have direct, on-site access to genomic material from highly purified cell populations for analysis with a variety of downstream molecular technologies. With the ability to detect as few as 1 target cell per mL (billion), the LiquidBiopsy platform delivers the ultra-high sample purity needed for next-gen sequencing, PCR, expression analysis as well as traditional FISH and IHC.

LiquidBiopsy is a risk-free, painless method to dynamically sample patients and sequentially measure their response to treatment. This is useful in clinical trials and to assess patients with complications from evolving cancer mutations. Cancer cells obtained by LiquidBiopsy can also be biobanked and analyzed retrospectively in the context of known clinical outcomes. The LiquidBiopsy method is complementary to traditional tissue biopsy which is necessarily performed infrequently after diagnosis.

The Mayo Clinic Cancer Center in Rochester, Minnesota and the Norris Comprehensive Cancer Center, part of the Keck School of Medicine at the University of Southern California, are the first centers to take part in the LiquidBiopsy Early Access program.

“Our technology has been available as a CLIA lab service for doctors and pharma since 2013,” said André de Fusco, Cynvenio’s CEO. “Our goal for the new LiquidBiopsy platform program is to enable those at the forefront of cancer research to unlock the complexities of tumor heterogeneity, concordance between sample types, and longitudinal patient monitoring.”

About Cynvenio Biosystems, Inc.

Cynvenio is a molecular information technology company focused on individualizing cancer treatment by providing longitudinal insights into each patient via the genomic analysis of their cancer from a standard blood draw.

Cynvenio’s LiquidBiopsy® and ClearID clinical assays for solid tumors are used as therapy finders to periodically assess patients’ individual mutations and match them with targeted cancer therapies and clinical trials. Both blood tests can be used to complement traditional tissue biopsy analysis, or as standalone tests to find therapies for patients in which tissue biopsy is deemed difficult or too risky to harvest.

Cynvenio is headquartered in Westlake Village, California (Los Angeles). For more information, visit http://www.cynvenio.com.

LiquidBiopsy® is a registered trademark of Cynvenio Biosystems, Inc.

Contacts

for Cynvenio Biosystems, Inc.
Trent Freeman, (310) 824-9000
tfreeman@olmsteadwilliams.com